Feedback
Amphetamines, Serum or Plasma, Quantitative
2010066
Ordering Recommendation

Detect exposure to amphetamines.

Mnemonic
AMPS SP
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry 
Performed
Tue
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA). 
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens. 
Remarks
 
Stability
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years 
Reference Interval
Effective August 17, 2015
Drugs CoveredCutoff Concentrations
Amphetamine20 ng/mL
Methamphetamine20 ng/mL
Methylenedioxyamphetamine (MDA)20 ng/mL
Methylenedioxymethamphetamine (Ecstasy, MDMA)20 ng/mL
Methylenedioxyethylamphetamine (Eve, MDEA)20 ng/mL

Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 20 ng/mL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
CPT Code(s)
80324; 80359 (Alt code: G0480)
Components
Component Test Code*Component Chart NameLOINC
2010068Amphetamine, S/P, Quant30112-7
2010069Methamphetamine, S/P, Quant3778-8
2010070MDA, S/P, Quant59837-5
2010071MDMA, S/P, Quant18356-6
2010072MDEA, S/P, Quant33016-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Adderall
  • Amphetamine
  • Benzedrine
  • Carbex
  • Deprenyl
  • Desoxyephedrine
  • Desoxyn
  • Dexedrine
  • Dextroamphetamine
  • Ecstasy
  • Eldepryl
  • Emsam
  • Eve
  • Lisdexamfetamine
  • MDA
  • MDEA
  • MDMA
  • Methamphetamine
  • Methedrine
  • Pain Management
  • Paremyd
  • Selegiline
  • Vicks Inhaler
  • Vynase
  • XTC
  • Zelapor